Guilin Sanjin Pharmaceutical Co Ltd Cash Flow Reinvestment Rate
Guilin Sanjin Pharmaceutical Co Ltd cash flow reinvestment rate. Guilin Sanjin Pharmaceutical Co Ltd (002275) has a Cash Flow Reinvestment Rate of 1.06x as of September 2025, reinvesting CN¥124.26 Million (capex CN¥124.26 Million ) from operating cash flow of CN¥117.62 Million. See 002275 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Cash Flow Reinvestment Rate of Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)
Cash flow reinvestment rate of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024. Historical reinvestment intensity for Guilin Sanjin Pharmaceutical Co Ltd across 19 annual periods. Explore Guilin Sanjin Pharmaceutical Co Ltd cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Guilin Sanjin Pharmaceutical Co Ltd Cash Flow Reinvestment Rate by Year (2006–2024)
Guilin Sanjin Pharmaceutical Co Ltd cash flow reinvestment rate by year from 2006 to 2024. Year-by-year capital reinvestment analysis for Guilin Sanjin Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Guilin Sanjin Pharmaceutical Co Ltd (002275) cash flow conversion.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.60x | CN¥355.43 Million | CN¥588.33 Million | CN¥82.18 Million | ▲ +94.5% |
| 2023 | 0.31x | CN¥170.62 Million | CN¥549.25 Million | CN¥76.40 Million | ▲ +37.2% |
| 2022 | 0.23x | CN¥119.74 Million | CN¥528.67 Million | CN¥62.27 Million | ▼ -49.5% |
| 2021 | 0.45x | CN¥184.03 Million | CN¥410.24 Million | CN¥144.09 Million | ▲ +17.2% |
| 2020 | 0.38x | CN¥228.91 Million | CN¥597.99 Million | CN¥205.47 Million | ▼ -73.6% |
| 2019 | 1.45x | CN¥678.71 Million | CN¥468.29 Million | CN¥226.14 Million | ▲ +122.8% |
| 2018 | 0.65x | CN¥358.96 Million | CN¥551.73 Million | CN¥89.96 Million | ▲ +15.1% |
| 2017 | 0.57x | CN¥219.27 Million | CN¥387.82 Million | CN¥61.53 Million | ▼ -4.6% |
| 2016 | 0.59x | CN¥318.27 Million | CN¥536.85 Million | CN¥65.36 Million | ▼ -8.9% |
| 2015 | 0.65x | CN¥259.42 Million | CN¥398.50 Million | CN¥125.02 Million | ▲ +22.2% |
| 2014 | 0.53x | CN¥211.28 Million | CN¥396.53 Million | CN¥211.28 Million | ▼ -46.5% |
| 2013 | 1.00x | CN¥312.85 Million | CN¥314.16 Million | CN¥312.85 Million | ▲ +46.5% |
| 2012 | 0.68x | CN¥205.63 Million | CN¥302.59 Million | CN¥205.63 Million | ▲ +82.9% |
| 2011 | 0.37x | CN¥126.75 Million | CN¥341.05 Million | CN¥126.75 Million | ▲ +7.8% |
| 2010 | 0.34x | CN¥98.44 Million | CN¥285.49 Million | CN¥98.44 Million | ▲ +129.1% |
| 2009 | 0.15x | CN¥54.68 Million | CN¥363.29 Million | CN¥54.68 Million | ▼ -25.6% |
| 2008 | 0.20x | CN¥38.64 Million | CN¥190.97 Million | CN¥38.64 Million | ▲ +89.1% |
| 2007 | 0.11x | CN¥17.59 Million | CN¥164.39 Million | CN¥17.59 Million | ▼ -20.1% |
| 2006 | 0.13x | CN¥29.16 Million | CN¥217.67 Million | CN¥29.16 Million | — |